Clinical trials: Hepatitis Delta Virus
Hepatitis C, Hepatic Steatosis
Oxidative Stress and Fatty Acids in Hepatitis C
Hepatitis C virus infection (HCV) is a major health concern in Canada and worldwide. Chronic HCV can cause progressive liver damage leading to inflammation, scarring and, in some cases, cirrhosis or liver cancer.
- Trial name
- NCT00444002
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Johane Allard
Hepatitis D
A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence…
- Trial name
- L47-HD-MN (NCT06505928)
- Testing
- hepalatide
- Where
- 2 sites in Mongolia
- Volunteers
- 90 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis D, Chronic
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
- Trial name
- LIMT (NCT02765802)
- Testing
- Peginterferon Lambda-1A
- Where
- 4 sites in Israel, New Zealand and 1 more
- Volunteers
- 33 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis B, Hepatitis C
Epidemiology of Hepatitis B, C and Delta in Reunion Island
Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on "Management of people infected with hepatitis B or hepatitis C…
- Conditions
- Hepatitis B, Hepatitis C, Hepatitis D
- Trial name
- HEPEPID (NCT03362866)
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Hepatitis B, Chronic
Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infection
This study was designed for changes in endotoxaemia, endotoxin-binding factors, sICAM-1 (soluble intracellular adhesion molecule-1), and cytokines during progression of chronic HBV infection.
- Trial name
- OCEHBV (NCT01107483)
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection.
- Trial name
- NCT07298330
- Testing
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Where
- 27 sites in United States, Belgium and 8 more
- Volunteers
- 80 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Observe and Describe the Prevalence of Hepatitis D Infection Among HBsAg Positive People
Epidemiological Survey of Hepatitis D Virus Infection in China
This cross-sectional study will screen out hepatitis D virus-infected patients in HBsAg-positive people. Observe and describe the prevalence of hepatitis D infection among HBsAg positive people.
- Trial name
- NCT04483518
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The First Hospital of Jilin University
HIV Infections, Hepatitis C
Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty…
- Trial name
- NCT00023218
- Testing
- Lopinavir/Ritonavir, Efavirenz
- Where
- 3 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
- Trial name
- NCT07128550
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 38 sites in Austria, France and 5 more
- Volunteers
- 150 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis D, Hepatitis C
Evaluation of Patients With Liver Disease
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Trial name
- NCT00001971
- Where
- United States
- Volunteers
- 8,050 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D
Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA
This observational study will be conducted in patients with chronic co-infection with hepatitis B and D viruses, with negative PCR for HDV RNA in peripheral blood and no signs of active liver inflammation according to blood…
- Trial name
- NCT06121427
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Center of target therapy
Viral Hepatitis
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
- Trial name
- NCT06903338
- Testing
- Tobevibart, Elebsiran
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 124 people
- Sponsor
- Vir Biotechnology, Inc.
HBV, HBV Coinfection
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
HDV is an RNA virus that infects only in the presence of HBV, affecting about 13% of HBsAg carriers. In Italy, prevalence ranges from 3.2% to 9.3%.
- Conditions
- HBV, HBV Coinfection, HCV, HIV Infections
- Trial name
- Bio-Delta (NCT07429864)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Evaluate Response to Treatment Both Biochemically and Virologically to Determine the Safety and Effectiveness of Bulevirtide Therapy in HDV Patients
Assessment of Response and Safety of Bulevirtide Treatment in Patients With Chronic Delta Virus Infection
1. The study is non-interventional, multicenter, non-profit 2. The primary objective of the study is to evaluate the safety and efficacy in clinical practice of the drug Bulevirtide in the treatment of patients with chronic HDV…
- Trial name
- ARISTOTLE (NCT07116044)
- Testing
- virological tests diagnostic tests
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- University of Molise
Chronic Viral Hepatitis B Without Delta-agent
Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
With the availability of potent nucloes(t)ide analogues (NA), such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV), suppression of serum HBV DNA to undetectable levels by polymerase chain reaction (PCR) assays became…
- Trial name
- IN-US-0205 (NCT01639066)
- Testing
- Tenofovir, Entecavir
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Asan Medical Center
Hepatitis D, Chronic, Hepatitis B Chronic Infection
Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection
Hepatitis D virus (HDV) is a major global health issue, with an estimated 12 million people living with the infection worldwide.
- Trial name
- NCT07610772
- Testing
- HepB mAb19
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 15 people
- Sponsor
- Aarhus University Hospital
Chronic Delta Hepatitis
Titrating-Dose of Lonafarnib in Combination With Ritonavir
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)
- Trial name
- LOWR-4 (NCT02527707)
- Testing
- lonafarnib, Ritonavir
- Volunteers
- 15 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis, Delta
"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.
The aim of the "Active Delta Referral" Project is to estimate the prevalence of anti-HDV positivity among HBsAg-positive patients hospitalized in the Department of Medicine at ASST Papa Giovanni XXIII in Bergamo, as well as among…
- Trial name
- HDV-Reflex (NCT07317011)
- Where
- Italy
- Volunteers
- 244 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Hepatitis C
Racial Difference in HCV/Host Interactions
The purpose of this study is to evaluate a group of African Americans and Caucasians with hepatitis C virus (HCV), compare their response rates to combination treatment with pegylated interferon alfa-2b and ribavirin, and…
- Trial name
- NCT00071916
- Where
- 3 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Blood Disease, Hepatitis, Viral, Human
Delta Hepatitis and Liver Disease in Hemophiliacs
To determine the prevalence of hepatitis delta virus (HDV) in a large cohort of hemophiliacs and to elucidate the role of HDV in the development and progression of liver disease in this population.
- Conditions
- Blood Disease, Hepatitis, Viral, Human, Hemophilia A, Liver Diseases
- Trial name
- NCT00005304
- Sponsor
- Baylor College of Medicine